CAPLYTA: payments to doctors
Payments that named CAPLYTA as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $50.2M
- Providers
- 72,636
- Transactions
- 622,180
- Average per transaction
- $81
The per-transaction average — $81 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 72,636 providers the average total is $692, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | $27,717,001 | 55.2% |
| ITI, Inc. | $22,521,769 | 44.8% |
| Johnson & Johnson | $167 | 0.0% |